Great-Sun Foods Co.,Ltd. (ASX: 603336) has been actively progressing with adjustments concerning its governance structure, asset allocation, and industrial layout. Amidst intensifying competition and heightened cost volatility within the fresh fruit and vegetable sector, the company is driving an evolution of its business model from a singular focus on fresh produce towards diversified operations. This is being achieved through internal reforms following a change in control, the disposal of non-core assets, and external acquisitions.
An examination of operational data reveals that while the company's traditional core business faces short-term pressure, its financial health is showing signs of improvement. In 2025, the company reported operating revenue of 1.052 billion yuan, marking a year-on-year decrease of 2.58%. Net profit attributable to shareholders was 17.813 million yuan, down 2.67% compared to the previous year. Against the backdrop of overall industry challenges, the company's revenue and profit remained relatively stable. More notably, the net cash flow from operating activities in 2025 reached 205 million yuan, a substantial increase of 478.07% year-on-year, indicating a significant improvement in cash flow. Concurrently, the company's total liabilities at year-end decreased to 354 million yuan, with the asset-liability ratio also declining, reflecting a further optimization of its capital structure.
Entering the first quarter of 2026, the company's cash reserves and asset quality have continued to improve, providing a financial foundation for subsequent asset integration, internal reforms, and industrial investments. For a company long entrenched in the fresh produce distribution business, the restoration of cash flow and the reduction of debt are crucial prerequisites for advancing its transformation.
On the governance front, Great-Sun Foods Co.,Ltd. completed a change in control in 2025. In July 2025, the company finalized the share transfer registration, with Suzhou Shenze Ruitai Enterprise Management Partnership (Limited Partnership) becoming the controlling shareholder. The change in control was completed in August of the same year. Following this change, the original actual controller, Huang Junhui, retained a portion of the company's shares. However, he signed relevant agreements, permanently relinquishing the voting, nomination, and proposal rights associated with those shares and committing that his total voting rights would not exceed 8%.
This arrangement helps clarify the boundaries of rights and responsibilities between the old and new shareholders, reduces potential governance uncertainties following the control transition, and provides a relatively stable governance environment for the new controlling shareholder and management team to advance medium- to long-term strategies.
Regarding assets, the company has simultaneously progressed with the disposal of low-efficiency assets. In November 2025, Great-Sun Foods Co.,Ltd. announced plans to publicly list and transfer 100% equity in two wholly-owned subsidiaries, Fujian Great-Sun Foods Co., Ltd. and Yantai Great-Sun Food Co., Ltd., through a property rights exchange. Currently, the transaction for the sale of these assets has been completed. By divesting certain low-efficiency or idle assets, the company aims to further streamline its business structure, recoup capital, and concentrate resources on its core operations and new industrial directions.
In terms of industrial layout, Great-Sun Foods Co.,Ltd., through its wholly-owned subsidiary Shanghai Tenghui Pharmaceutical Technology Co., Ltd., invested 700 million yuan to acquire a 41.128% stake in Jiangxi Shimei Pharmaceutical Co., Ltd. The company achieved substantive control through the transfer of voting rights and governance arrangements. Information indicates that Shimei Pharmaceutical's business covers drug research and development, production, and sales, with its main products concentrated in essential prescription drug areas.
Overall, over the past year, Great-Sun Foods Co.,Ltd. has completed multiple adjustments concerning control, asset structure, financial quality, and industrial layout. The significant improvement in cash flow, the reduction in debt levels, the clearance of low-efficiency assets, and the integration of the pharmaceutical business into the listed company's system constitute the main framework of the company's current transformation. Subsequently, the operational performance of Shimei Pharmaceutical, its contribution to consolidated financials, and the effectiveness of integrating old and new businesses will be key factors in observing the success of the company's strategic upgrade.
Comments